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Poster Session II S361performed when indicated clinically. CT scan of lung was performed
to confirm the diagnosis of lung GVHD and to exclude other infec-
tious causes. Bronchoscopic lavage was performed to exclude poten-
tial infectious cause if needed. Potential clinical risk factors for lung
GVHD were examined including conditioning, age, gender, source
of stem cell, diagnosis, disease status and previous episode of acute
GVHD.
Results:With median follow up of 1,122 days, 68 patients (16.9%)
had a diagnosis of chronic GVHD of lung with median onset of 349
days (range 71-1,880 days; 95% CI [299-398 days]), 53(78%) of
whom patients received myeloablative conditioning. Fifty
one(75%) patients received matched sibling donor transplant versus
17(25%) patients received unrelated donor. Overall survival rates re-
mained similar in both cohorts.
In the univariate analyses, other clinical risk factors were not asso-
ciated with the risk of chronic GVHD of lung: conditioning (p 5
0.9), age with cut off of 60 years (p5 0.4), donor type (p5 0.5), grade
II-IV acute GVHD (p 5 0.7), grade III-IV acute GVHD(p 5 0.4),
development of CMV reactivation (p 5 0.6). However, incidence
of chronic GVHD lung was significantly higher in the group receiv-
ing PBSC (13.86 2.4% at 1 year; 23.063.2% at 2 years) than in those
receiving BM (6.862.5% at 1 year; 1663.8% at 2 years; p 5 0.02,
hazard ratio 1.937, 95%CI [1.100-3.410]). Multivariate analyses
also confirmed PBSC transplantation as an independent risk factor
for chronic GVHD of lung (p 5 0.005, hazard ratio 2.359, 95%CI
[1.290-4.314]).
Conclusion: The use of PBSC increases the risk of lung GVHD
compared to the use of BM for allogeneic HCT. Closer monitoring
is warranted to detect lung GVHD early after PBSCT.425
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Introduction: Rapamycin (RAPA) inhibits the serine/threonine ki-
nase mammalian Target of Rapamycin, a crucial immune regulator.
Dendritic cells (DC) exposed to RAPA (RAPA-DC) enrich for
CD4+FoxP3+ regulatory T cells and induce alloreactive T cell apo-
ptosis. RAPA-DC promote experimental allograft survival, yet para-
doxically secrete increased IL-12, which is central for the generation
of IFN-g+CD4+ T helper type 1 cells. IFN-g can be pro-apoptotic
and IL-12-driven IFN-g inhibits graft-versus-host disease
(GVHD) following hematopoietic stem cell transplantation.We hy-
pothesized that IL-12hi RAPA-DC, unlike control (CTR)-DC
would be effective in the prevention of GVHD by supporting
IFN-g-mediated apoptosis of alloreactive T cells.
Methods: DC were generated from C57BL/6 (H2-b) or BALB/c
(H2-d) bone marrow (BM) in 7 day (d) culture in the presence or ab-
sence of RAPA. DC remained unstimulated or were LPS-stimulated
(100 ng/ml) for an additional 18 hours. CD11c+ DC were used as
stimulators of allogeneic CD4+ T cells in 5 d mixed leukocyte reac-
tion (MLR) with or without anti-IFN-g antibody. T cell apoptosis
was quantified using an Annexin V-PE Apoptosis Detection kit. In-
tracellular FoxP3 expression was determined by flow cytometry. The
capacity of DC to prevent GVHDwas assessed in irradiated BALB/c
mice reconstituted with 5x106 T cell-depleted B6 BM on d0. Recip-
ient mice received 1x106 CD11c+ BALB/c DC (CTR-, RAPA-, or
LPS-exposed DC) on d0 and 1x106 B6 T cells on d1. Mice were
monitored daily, and moribund mice or those with .20% weight
loss were euthanized.
Results: Compared to CTR-DC, especially when LPS-stimulated,
RAPA-DC induced increased apoptosis (Annexin V+7-AAD+) of al-
loreactive CD4+ T cells in MLR (Table 1). Neutralization of IFN-g
in co-cultures containing LPS-stimulated RAPA-DC decreased
levels of apoptosis to those of LPS-exposed CTR-DC. Depletion of
IFN-g did not impact on the Treg-enriching capacity of RAPA-DC.Further, whereas CTR-DC and LPS-exposed CTR-DC did not
prolong survival, LPS-treated RAPA-DC prolonged survival com-
parable to syngeneic controls. RAPA-DC prolonged survival nearing
statistical significance.
LPS-exposed RAPA-DC induce apoptosis of alloreactive CD4+
T cells via an IFN-g dependentmechanism and abrogate acute
GVHD
% CD4+ Annexin V+ Median
Group 7-AAD+ Survival (d)1 Syngeneic - >50d2 CTR-DC 7.1 ± 0.2 8e3 RAPA-DC 13.9 ± 1.6a 25f4 RAPA-DC + aIFNg 21.8 ± 13.7 -
5 CTR-DC + LPS 14.6 ± 3.6 11g6 RAPA-DC + LPS 30.6 ± 3.4b,c >50h7 RAPA-DC + LPS + aIFNg 18.4 ± 1.3 -
8 GVHD - 15ap 5 0.03 compared to group 2.
bp 5 0.04 compared to group 5.
cp 5 0.04 compared to group 7.
dp 5 0.03 compared to group 8.
ep 5 0.92 compared to group 8.
fp 5 0.07 compared to group 8.
gp 5 0.67 compared to group 8.
hp 5 0.005 compared to group 8 by 2-tailed Student’s t-test.
Conclusions: Increased apoptosis of CD4+ allogeneic T cells in-
duced by LPS-stimulated IL-12hi RAPA-DC is mediated through
IFN-g. Thus, increased IL-12 may support IFN-g-mediated activa-
tion-induced cell death while sparing regulatory T cells and underlie
the capacity of LPS-exposed RAPA-DC to prevent GVHD.426
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IL-22 is a recently characterized cytokine that is produced by
helper T cells and innate lymphoid cells (ILC). Expression of its re-
ceptor (IL-22R) is limited to non-hematopoietic stromal cells, and it
mediates protection of intestinal epithelium during experimental co-
litis by providing a signal for epithelial cell survival, proliferation,
and wound healing. We investigated the role of IL-22 in GVHD
during MHC-mismatched C57BL/6 (B6) into BALB/c murine
bone marrow transplantation (BMT). Elimination of IL-22 with
neutralizing antibody led to increased GVHD mortality post-
BMT in comparison to isotype control. IL-22 KO BMT recipients
demonstrated significantly increased GVHD mortality. The critical
role of recipient-derived IL-22 was confirmed in a minor antigen-
mismatched LP into B6 BMTmodel, and IL-22 KO recipients again
demonstrated significantly increased mortality during GVHD and
histopathologic evidence of GVHD in the small and large intestine
and liver. IL-22 ELISA on tissue homogenates following BMT
with wild type donors and recipients indicated that IL-22 levels
were increased post-BMT in small and large intestine. However,
IL-22 was significantly reduced in both tissues during GVHD. We
identified IL-22-producing host ILC in small intestine lamina prop-
ria two weeks post-BMT. ILC were the only IL-22-producing pop-
ulation that could be identified post-BMT, and these ILC were
significantly reduced during GVHD. IL-22R expression was identi-
fied by immunohistochemistry in intestinal crypts where the stem/
progenitor cell niche is located, and immunofluorescence demon-
strated IL-22R expression on intestinal progenitors at the crypt
apex and on intestinal stem cells (ISC) located between lysozyme-ex-
pressing Paneth cells. Use of Lgr5-LacZ reportermice indicated that
ISC were targets of GVHD, and histologic assessment of the ISC
S362 Poster Session IIniche demonstrated exacerbated loss of ISC in IL-22 KO mice dur-
ing GVHD.
In summary, IL-22 was produced post-BMT by host ILC that
were eliminated during GVHD, and IL-22 deficiency increased
GVHD morbidity and mortality. While IL-22 deficiency did not
significantly alter the donor immune response, it did lead to in-
creased GVHD pathology, loss of epithelial integrity, and loss of
ISC. IL-22 is thus critical for protection of host epithelium during
GVHD. This may be exploited in the future to reduce clinical
GVHD without limiting the curative potential of the transplant.427
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Introduction: We have recently established an immunodeficient
NOD/SCID/IL2Rgcnull (NSG) mouse model that allows the reli-
able engraftment of primary human acute myeloid leukemia
(AML) blasts, particularly those with FLT3-ITD mutations. We
now use these mice as a platform to evaluate the graft-versus-leuke-
mia (GvL) effect of human leukemia-reactive T cells in vivo. To sys-
tematically optimize essential parameters for survival and effector
function of human T cells in NSG mice, large numbers of AML-re-
active cytotoxic T lymphocytes (CTL) were generated in vitro by
stimulation of healthy donor CD8+ T cells with FLT3-ITD+ AML
blasts in either singleHLA-class I-mismatched orHLA-matched sit-
uations.
Methods: 5x10e5 AML blasts were injected into 6-8 week-old irra-
diated (150cGy) NSG mice to achieve 1-5% AML engraftment in
bone marrow (BM) within 18 days (d) resembling minimal residual
disease. Subsequently, 5x10e6 alloreactive CD8+ CTL expanded
over 14, 21, 28, and 56 d in vitro were transfused into mice to inves-
tigate differences in homing, survival, and GvL reactivity in vivo.
Controls included AML-engrafted mice without CTL as well as
mice receiving CTL of irrelevant antiviral specificity. All mice re-
ceived human interleukin (IL)2, IL7-Fc and IL15 at time of T cell
injection. AML-reactivity was analyzed in kinetic studies 2 h, 24 h,
48 h and 7 d after CTL transfer.
Results: We observed complete eradication of patient-derived
FLT3-ITD+ AML blasts in BM, spleen and peripheral blood of
mice one week after transfer of single locus HLA-B mismatched
CTL that had been cultured for 14, 21, or 28 d, respectively. In con-
trast, control mice showed 25-61% (median 35%) leukemia infiltra-
tion in BM. Kinetic analysis demonstrated almost complete AML
remission as early as 48 h after T cell transfer. Ex vivo analysis of
CTL re-isolated from murine spleens 24 and 48 h after injection
showed persistent reactivity to AML blasts, but not to NSG-derived
murine dendritic cells. Interestingly, CTL expanded over 56 d in vi-
tro appeared less capable to eradicate AML in vivo. Results were re-
producible in 2 different donor-patient pairs and, moreover, are in
line with ongiong studies in HLA-matched systems.
Conclusion: We show herein that NSG mice engrafted with pri-
mary human AML blasts can be successfully treated with human al-
loreactive CTL. The model will be further optimized to serve as
a general platform for testing the GvL effect of T cell grafts before
adoptive transfer into humans.428
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Bronchiolitis obliterans syndrome (BOS) after allogeneic
HSCT is a deadly manifestation of cGVHD. Current treatments
are inferior and yield transient responses with published overall
survival of 44% at 2 years. Although the pathogenesis of BOS af-
ter HSCT is unknown, a similar disease, BOS after lung trans-
plant is associated with elevated leukotriene levels. We present
preliminary results from a prospective, open label, phase II trial
testing the efficacy of montelukast, a leukotriene inhibitor, for
the treatment of BOS after HSCT. BOS diagnostic criteria in-
cluded: FEV1\75%, FEV1/VC \ 0.7 or air trapping on CT
and RV.120% or RV/TLC.120% in the absence of infection
and presence of another cGVHD manifestation. Subjects had sta-
ble or declining FEV1 on stable or decreasing immunosuppres-
sion. Twenty patients have been enrolled. One withdrew prior
to treatment and one withdrew after study medication initiation;
16/20 patients have reached the primary endpoint (6 months) on
study medication (10 mg qhs). Study participants age ranged
from 15-64 years, 12/20 female, with baseline FEV1 from 24
to 73% predicted. All patients met criteria for response on the
clinical trial with less than 15% decline in FEV1 % predicted
at the primary endpoint. FEV1 increased 5-13% predicted in 5
participants, remained stable in 6 (change \5%), and declined
5-13% in 5. Comparison of patient pre-study FEV1 decline to
on-study FEV1 values was generated using the slope of FEV1
volume vs. days post-transplant. The difference in pre- and pri-
mary endpoint slope revealed: 14/16 improvement and 2/16 de-
cline. Six minute walk test demonstrated that 4/16 patients had
significant increases in walk distance that exceeded the minimally
important difference, 2 of which had declining FEV1%. 2/20 had
a significant decline in walk test accompanied by a decline in
FEV1% predicted. Of 10 patients eligible for the 2 year end-
point, 7/10 are alive with 2 patients with durable FEV1 improve-
ments from baseline (FEV1+ 6%, +14%), 2 stable (FEV1 0%,
+1%), 3 with decline from baseline (FEV1 -4%, -4%, -8%).
Montelukast was well-tolerated with only one grade II probable
attributable adverse event (insomnia) during the six-month collec-
tion period. These findings suggest that montelukast is a promis-
ing therapy for BOS after allogeneic HSCT.429
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Aim: The immunological parameters governing the presentation
pathways for allogeneic peptides to induce graft-versus-host disease
(GVHD) are unclear. This is critical for the development of clinical
therapies based on antigen presentation to control deleterious allor-
eactive responses.
Method and Result: We developed a GVHD model following
a bone marrow transplant (BMT) system whereby presentation
of a processed recipient peptide within MHC class II can be spa-
tially and temporally quantified. The presentation of peptide
within MHC class II by recipient antigen presenting cell (APC)
resulted in GVHD mortality within ten days. While donor
APC could induce lethal acute GVHD, recipient APC were
100-1000 times more potent. Antigen presentation by recipient
APC resulted in accumulation of antigen-specific T cells within
